ARAY · XBRL financial data

Accuray financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARAY's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue from contracts with customers	396,289	429,909	447,605	446,551	458,505	401,947
Cost of revenue	236,782	269,954	293,645	303,630	311,538	290,493
Gross profit	159,507	159,955	153,960	142,921	146,967	111,454
Research and development	52,729	57,752	57,129	49,732	47,942	37,753
General and administrative	41,723	44,391	48,271	50,066	47,871	45,398
Total operating expenses	137,272	151,807	151,578	142,417	139,128	137,896
Operating income (loss)	22,235	8,148	2,382	504	7,839	(26,442)
Interest income	—	—	—	1,231	1,192	819
Interest expense	16,893	8,129	10,632	11,624	12,954	32,905
Other income (expense)	(27,666)	(10,391)	(11,742)	(2,538)	559	5,011
Income tax expense (benefit)	1,752	3,345	2,492	3,725	2,725	1,946
Net income (loss)	(6,311)	(5,347)	(9,280)	(15,545)	(1,591)	(49,194)
Earnings per share, basic USD per share	(0.07)	(0.06)	(0.10)	(0.16)	(0.02)	(0.40)
Earnings per share, diluted USD per share	(0.07)	(0.06)	(0.10)	(0.16)	(0.02)	—
Weighted average shares, basic thousands of shares	92,031	92,095	94,884	98,272	102,768	122,635
Weighted average shares, diluted thousands of shares	92,031	92,095	94,884	98,272	102,768	—

Fiscal years (ARAY's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	116,369	88,737	89,402	68,570	57,416	40,623
Accounts receivable	—	—	—	92,001	83,192	67,409
Inventory	125,929	142,254	145,150	138,324	141,020	147,075
Prepaid and other current assets	21,547	23,794	27,612	23,006	33,501	31,783
Total current assets	352,773	350,890	338,033	323,236	317,465	287,777
Property and equipment, net	12,332	12,685	20,926	24,774	28,658	27,316
Right-of-use asset	22,522	16,798	25,853	33,773	33,115	27,512
Goodwill	57,960	57,840	57,681	57,672	57,802	57,911
Total assets	480,098	472,849	479,214	468,627	470,239	443,676
Accounts payable	19,467	31,337	33,739	50,020	34,033	40,554
Current portion of long-term debt	3,790	8,563	5,721	7,756	12,734	1,500
Total current liabilities	192,359	208,858	198,637	195,267	192,579	191,405
Long-term debt	170,007	171,907	171,562	164,400	123,786	146,370
Lease liability, non-current	17,441	10,453	23,602	32,373	32,482	27,768
Total liabilities	411,258	419,660	425,555	423,543	389,070	401,977
Accumulated deficit	(488,024)	(492,522)	(502,136)	(517,681)	(519,272)	(568,466)
Total stockholders' equity	68,840	53,189	53,659	45,084	81,169	41,699
Total liabilities and equity	480,098	472,849	479,214	468,627	470,239	443,676
Common shares outstanding (cover page) thousands of shares	90,829	93,500	96,590	100,268	112,677	119,439

Fiscal years (ARAY's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(6,311)	(5,347)	(9,280)	(15,545)	(1,591)	(49,194)
Stock-based compensation	9,332	10,600	10,053	9,484	10,201	6,455
Depreciation and amortization	6,389	5,513	4,527	5,905	6,150	7,942
Net cash from operating activities	38,512	(2,400)	15,539	(11,904)	2,860	(6,981)
Purchases of property and equipment	2,320	4,717	12,614	3,601	4,272	5,861
Net cash from investing activities	(2,399)	(4,717)	(12,681)	(3,601)	(8,523)	(12,279)
Proceeds from issuing common stock	3,030	3,889	2,200	2,247	1,627	665
Share repurchases	14,080	0	0	—	—	—
Repayments of long-term debt	115,924	0	0	—	—	—
Net cash from financing activities	(28,805)	(15,369)	(2,112)	(3,951)	(4,252)	6,977
Net change in cash	8,290	(28,047)	1,048	(20,810)	(8,258)	(13,367)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Fonar	53,650	26,472	1,580*	not reported	—	Q3 FY26 10-QMar 31, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Microbot Medical	3,152	241	(4,989)*	67.2M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
Pulmonx	52,690	22,835	(3,183)*	43.6M	8.5 quarters	Q3 FY26 10-QSep 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.